S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Millionaire Trader Drops Bombshell… “The Only Trade You Will Ever Need” (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Millionaire Trader Drops Bombshell… “The Only Trade You Will Ever Need” (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Millionaire Trader Drops Bombshell… “The Only Trade You Will Ever Need” (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
3 Free Stock Picks per Day (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
Millionaire Trader Drops Bombshell… “The Only Trade You Will Ever Need” (Ad)
Takeaways on debt ceiling: McCarthy's balancing act, Biden's choice and the challenges ahead
Debt ceiling agreement gets thumbs up from business groups, jeers from some on political right
NASDAQ:LIFE

aTyr Pharma (LIFE) Price Target & Analyst Ratings

$2.35
-0.01 (-0.42%)
(As of 05/26/2023 08:47 PM ET)
Compare
Today's Range
$2.30
$2.40
50-Day Range
$1.72
$2.57
52-Week Range
$1.55
$4.28
Volume
320,000 shs
Average Volume
501,200 shs
Market Capitalization
$127.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67

aTyr Pharma Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 5 Analyst Ratings

Consensus Analyst Price Target

$19.00
708.51% Upside
High Prediction$35.00
Average Prediction$19.00
Low Prediction$9.00
TypeCurrent
5/29/22 to 5/29/23
1 Month Ago
4/29/22 to 4/29/23
3 Months Ago
2/28/22 to 2/28/23
1 Year Ago
5/29/21 to 5/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$19.00$19.00$24.50$16.67
Predicted Upside708.51% Upside848.20% Upside704.60% Upside124.57% Upside
Get aTyr Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.


LIFE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LIFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

aTyr Pharma Stock vs. The Competition

TypeaTyr PharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyBuyHold
Predicted Upside708.51% Upside1,396.20% Upside186.84% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/11/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$9.00 ➝ $13.00+584.21%
3/10/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$35.00+1,669.81%
3/10/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$19.00+860.76%
3/6/2023Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$9.00+316.67%
3/3/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
(Data available from 5/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












LIFE Price Target - Frequently Asked Questions

What is aTyr Pharma's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for aTyr Pharma stock is Buy based on the current 5 buy ratings for LIFE. The average twelve-month price prediction for aTyr Pharma is $19.00 with a high price target of $35.00 and a low price target of $9.00. Learn more on LIFE's analyst rating history.

Do Wall Street analysts like aTyr Pharma more than its competitors?

Analysts like aTyr Pharma more than other Medical companies. The consensus rating score for aTyr Pharma is 3.00 while the average consensus rating score for medical companies is 2.66. Learn more on how LIFE compares to other companies.

Does aTyr Pharma's stock price have much upside?

According to analysts, aTyr Pharma's stock has a predicted upside of 848.20% based on their 12-month price targets.

What analysts cover aTyr Pharma?

aTyr Pharma has been rated by HC Wainwright, Piper Sandler, Roth Capital, Roth Mkm, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:LIFE) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -